Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Chemotherapy in Advanced NSCLC (PS 2)
NCT00085839Phase 2Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Feb 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OSI Pharmaceuticals. Primary endpoint: Progression-free Survival. Started Feb 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00085839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085839.